Cargando…

Unexpected Interruptions in the Inhaled Epoprostenol Delivery System: Incidence of Adverse Sequelae and Therapeutic Consequences in Critically Ill Patients

Inhaled epoprostenol is a continuously delivered selective pulmonary vasodilator that is used in patients with refractory hypoxemia, right heart failure, and postcardiac surgery pulmonary hypertension. Published data suggest that inhaled epoprostenol administration via vibrating mesh nebulizer syste...

Descripción completa

Detalles Bibliográficos
Autores principales:	Block, Jason M., Madhok, Jai, Owyang, Clark G., Merriman, Kristen R., Ruoss, Stephen J., Rao, Vidya K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522871/ https://www.ncbi.nlm.nih.gov/pubmed/34671745 http://dx.doi.org/10.1097/CCE.0000000000000548

Ejemplares similares

Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension
por: Preston, Ioana R., et al.
Publicado: (2013)

Successful use of inhaled epoprostenol as rescue therapy for pediatric ARDS
por: Urich, Alissa, et al.
Publicado: (2020)

Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19
por: Sonti, Rajiv, et al.
Publicado: (2020)

HIGH-FLOW NASAL CANULA AND INHALED EPOPROSTENOL RESPONSE IN COVID-19
por: KHURANA, NEHARIKA, et al.
Publicado: (2022)

Epoprostenol: Flushing or Erythroderma?
por: Martínez-Martínez, María Luisa, et al.
Publicado: (2013)

Evaluation of the Efficacy and Safety of Inhaled Epoprostenol and Inhaled Nitric Oxide for Refractory Hypoxemia in Patients With Coronavirus Disease 2019
por: DeGrado, Jeremy R., et al.
Publicado: (2020)

Refractory Cardiogenic Shock from Right Ventricular Infarction Successfully Managed with Inhaled Epoprostenol
por: Held, Natalie, et al.
Publicado: (2017)

Inhaled epoprostenol therapy for pulmonary hypertension: Improves oxygenation index more consistently in neonates than in older children
por: Brown, Anna T., et al.
Publicado: (2012)

Effects of Inhaled Epoprostenol and Prone Positioning in Intubated Coronavirus Disease 2019 Patients With Refractory Hypoxemia
por: Li, Jie, et al.
Publicado: (2020)

In-vitro and in-vivo comparisons of high versus low concentrations of inhaled epoprostenol to adult intubated patients
por: Li, Jie, et al.
Publicado: (2021)

Epoprostenol Exposure During Pregnancy
por: Naoum, Emily E., et al.
Publicado: (2023)

Epoprostenol: Exacerbation of thrombocytopenia : case report
Publicado: (2021)

Stress Cardiomyopathy Precipitated by Withdrawal of Epoprostenol
por: Gionfriddo, William J., et al.
Publicado: (2020)

The Use of Inhaled Epoprostenol for Acute Respiratory Distress Syndrome Secondary Due To COVID-19: a Case Series
por: Imtiaz, Komal, et al.
Publicado: (2021)

UTILIZING COMBINATION THERAPY WITH INHALED EPOPROSTENOL AND LOOP DIURETICS IN ACUTE HYPOXIC RESPIRATORY FAILURE FROM COVID-19
por: PINO, MARI-ELENA, et al.
Publicado: (2022)

Epoprostenol sodium for treatment of pulmonary arterial hypertension
por: Saito, Yukihiro, et al.
Publicado: (2015)

Use of Epoprostenol in the Treatment of Pulmonary Arterial Hypertension
por: Mohammadi, Asma, et al.
Publicado: (2021)

Alteplase/epoprostenol: Lack of efficacy: case report
Publicado: (2022)

Epoprostenol‐associated ascites in pulmonary arterial hypertension
por: Schoenberg, Noah C., et al.
Publicado: (2022)

Letter to the Editor: “Use of inhaled epoprostenol with high flow nasal oxygen in non-intubated patients with severe COVID-19”
por: Chiles, Joe W., et al.
Publicado: (2022)

COMPARISON OF HIGHER VERSUS LOWER DOSE STEROID ADMINISTRATION IN PATIENTS WITH COVID-19 AND ACUTE HYPOXEMIC RESPIRATORY FAILURE ON INHALED EPOPROSTENOL
por: RIEGO, MARIA ATHENA, et al.
Publicado: (2022)

A Comparison of Inhaled Epoprostenol in Patients With Acute Respiratory Distress Syndrome and COVID-19-Associated Acute Respiratory Distress Syndrome
por: Robinson, John, et al.
Publicado: (2022)

An Unexpected Case of Intrapartum Pneumomediastinum
por: Madhok, Drishti, et al.
Publicado: (2019)

Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy
por: Timofeev, Julia, et al.
Publicado: (2013)

Microbial challenge test of a novel epoprostenol sodium formulation
por: Bandilla, Dirk, et al.
Publicado: (2017)

Goiter in a Patient with Pulmonary Arterial Hypertension Treated with Epoprostenol
por: Abughazaleh, Shaadi, et al.
Publicado: (2020)

Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
por: Sitbon, Olivier, et al.
Publicado: (2017)

Nitric oxide versus epoprostenol for refractory hypoxemia in Covid-19
por: Poonam, Pai B. H., et al.
Publicado: (2022)

PSAT054 Isolated ACTH Deficiency in a Patient on Epoprostenol
por: Riordan, Marianne, et al.
Publicado: (2022)

Tuberculin Skin Test Reaction and Sarcoidosis – An Unexpected Sequela
por: Jayasree, Puravoor, et al.
Publicado: (2020)

Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study
por: Frantz, Robert P., et al.
Publicado: (2015)

Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
por: Calcaianu, George, et al.
Publicado: (2017)

Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension
por: Abston, Eric, et al.
Publicado: (2020)

Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery
por: Guan, Zheng, et al.
Publicado: (2018)

Occult catheter rupture causing episodic symptoms in a patient treated with epoprostenol
por: LeVarge, Barbara L., et al.
Publicado: (2017)

The impact of nebulized epoprostenol and iloprost on hemoglobin oxygen affinity: an ex vivo experiment
por: Woyke, Simon, et al.
Publicado: (2022)

Reversible Cardiac Hypertrophy in Pulmonary Arterial Hypertension Treated With High-Dose Epoprostenol
por: Izumi, Keiichi, et al.
Publicado: (2022)

Interrupted Blood Feeding in Ticks: Causes and Consequences
por: Tahir, Djamel, et al.
Publicado: (2020)

Post-tuberculosis sequelae and their socioeconomic consequences: worth investigating
por: Sotgiu, Giovanni, et al.
Publicado: (2021)

Antimalarial drugs: unexpected evolutionary consequences
por: Schneider, Petra, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ehpiut62lloc5mokobeuofbnt2